Pharmacogenomics of antimicrobial agents

Pharmacogenomics

Volumn 15, Issue 15, 2014, Pages 1903-1930

  Aung, Ar Kar ^a   Haas, David W ^b   Hulgan, Todd ^b   Phillips, Elizabeth J ^b,c  

^a ALFRED HOSPITAL   (Australia)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c MURDOCH UNIVERSITY   (Australia)

Author keywords

antibacterials; antifungals; antimalarials; antivirals; pharmacogenomics

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMODIAQUINE; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIINFECTIVE AGENT; ANTIMALARIAL AGENT; ANTIRETROVIRUS AGENT; ANTIVIRUS AGENT; ARTEMISININ DERIVATIVE; ARTESUNATE; BIGUANIDE DERIVATIVE; CHLORPROGUANIL PLUS DAPSONE; COTRIMOXAZOLE; DAPSONE; EFAVIRENZ; ESOMEPRAZOLE; ETHAMBUTOL; FLUCLOXACILLIN; ISONIAZID; LANSOPRAZOLE; LINEZOLID; MEFLOQUINE; OMEPRAZOLE; PROTON PUMP INHIBITOR; PYRAZINAMIDE; RABEPRAZOLE; RIBAVIRIN; RIFAMPICIN; SULFAMETHOXAZOLE; UNINDEXED DRUG; VORICONAZOLE; 2',3' DIDEOXYNUCLEOSIDE DERIVATIVE; ABACAVIR; HLA B ANTIGEN; HLA-B57 ANTIGEN;

ABDOMINAL PAIN; AGRANULOCYTOSIS; ANEMIA; AREA UNDER THE CURVE; BONE MARROW SUPPRESSION; CENTRAL NERVOUS SYSTEM DISEASE; CHOLESTATIC HEPATITIS; DOSE RESPONSE; DRESS SYNDROME; DRUG BLOOD LEVEL; DRUG COMPETITION; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG EFFICACY; DRUG ELIMINATION; DRUG FATALITY; DRUG METABOLISM; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; GASTRITIS; GENE MUTATION; GENETIC ASSOCIATION; GRAM NEGATIVE INFECTION; HELICOBACTER INFECTION; HEMOLYTIC ANEMIA; HEPATITIS C; HEREDITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERLACTATEMIA; HYPERSENSITIVITY; IMMUNE RESPONSE; LEPROSY; LIVER TOXICITY; MALARIA; MALARIA FALCIPARUM; MAXIMUM PLASMA CONCENTRATION; MENTAL DISEASE; NEUTROPENIA; OPTIC NERVE DISEASE; OTOTOXICITY; PEPTIC ULCER; PERCEPTION DEAFNESS; PERIPHERAL NEUROPATHY; PHARMACOGENOMICS; PNEUMOCYSTOSIS; RASH; REPEATED DRUG DOSE; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; STEVENS JOHNSON SYNDROME; TOXIC EPIDERMAL NECROLYSIS; TOXIC HEPATITIS; TUBERCULOSIS; VISUAL DISORDER; DRUG HYPERSENSITIVITY; GENETIC VARIABILITY; GENETICS; PHARMACOGENETICS;

ANTI-INFECTIVE AGENTS; DIDEOXYNUCLEOSIDES; DRUG HYPERSENSITIVITY; GENETIC VARIATION; HLA-B ANTIGENS; HUMANS; PHARMACOGENETICS;

EID: 84919823023     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.14.147     Document Type: Review

References (268)

1. Lim SS, Vos T, Flaxman AD, et al. A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990-2010: A systematic analysis for the Global Burden of Disease Study 2010. Lancet 380(9859), 2224-2260 (2013
2. Yang G, Wang Y, Zeng Y, et al. Rapid health transition in China, 1990-2010: Findings from the Global Burden of Disease Study 2010. Lancet 381(9882), 1987-2015 (2013
3. Davison DB, Barrett JF. Antibiotics and pharmacogenomics. Pharmacogenomics 4(5), 657-665 (2003
4. McNicholl JM, Downer MV, Udhayakumar V, Alper CA, Swerdlow DL. Host-pathogen interactions in emerging and re-emerging infectious diseases: A genomic perspective of tuberculosis, malaria, human immunodeficiency virus infection, hepatitis B, and cholera. Annu. Rev. Public Health 21(1), 15-46 (2000
5. Tan S-L, Ganji G, Paeper B, Proll S, Katze MG. Systems biology and the host response to viral infection. Nat. Biotechnol. 25(12), 1383-1389 (2007
6. Ho RH, Kim RB. Transporters and drug therapy: Implications for drug disposition and disease. Clin. Pharmacol. Ther. 78(3), 260-277 (2005
7. Minuesa G, Huber-Ruano I, Pastor-Anglada M, Koepsell H, Clotet B, Martinez-Picado J. Drug uptake transporters in antiretroviral therapy. Pharmacol. Ther. 132(3), 268-279 (2011
8. Attar M, Lee VH. Pharmacogenomic considerations in Drug delivery. Pharmacogenomics 4(4), 443-461 (2003
9. Pavlos R, Phillips EJ. Individualization of antiretroviral therapy. Pharmacogenomics Personal. Med. 5, 1 (2012
10. Wedi B. Definitions and mechanisms of drug hypersensitivity. Expert Rev. Clin. Pharmacol. 3(4), 539-551 (2010
11. Johansson S, Hourihane JB, Bousquet J, et al. A revised nomenclature for allergy: An EAACI position statement from the EAACI nomenclature task force. Allergy 56(9), 813-824 (2001
12. Posadas S, Pichler W. Delayed drug hypersensitivity reactions - new concepts. Clin. Exp. Allergy 37(7), 989-999 (2007
13. Pavlos R, Mallal S, Phillips E. HLA and pharmacogenetics of drug hypersensitivity. Pharmacogenomics 13(11), 1285-1306 (2012
14. Gil JP. Amodiaquine pharmacogenetics. Pharmacogenomics 9(10), 1385-1390 (2008
15. Cavaco I, Piedade R, Msellem M, Bjorkman A, Gil J. Cytochrome 1A1 and 1B1 gene diversity in the Zanzibar islands. Trop. Med. Int. Health 17(7), 854-857 (2012
16. Piedade R, Gil JP. The pharmacogenetics of antimalaria artemisinin combination therapy. Expert Opin. Drug Metabol. Toxicol. 7(10), 1185-1200 (2011
17. Kerb R, Fux R, Mörike K, et al. Pharmacogenetics of antimalarial drugs: Effect on metabolism and transport. Lancet Infect. Dis. 9(12), 760-774 (2009
18. Phompradit P, Muhamad P, Cheoymang A, Na-Bangchang K. Preliminaryinvestigation of the contribution of CYP2A6, CYP2B6, and UGT1A9 polymorphisms on artesunate-mefloquine treatment response in Burmese patients with Plasmodium falciparum malaria. Am. J. Trop. Med. Hyg. 91(2), 361-366 (2014
19. Roederer MW, McLeod H, Juliano JJ. Can pharmacogenomics improve malaria drug policy? Bull. World Health Organ. 89(11), 838-845 (2011
20. Noedl H, Socheat D, Satimai W. Artemisinin-resistant malaria in Asia. N. Engl. J. Med. 361(5), 540-541 (2009
21. di Iulio J, Fayet A, Arab-Alameddine M, et al. In vivo analysis of efavirenz metabolism in individuals with impaired CYP2A6 function. Pharmacogenet. Genomics 19(4), 300-309 (2009
22. Haas DW, Kwara A, Richardson DM, et al. Secondary metabolism pathway polymorphisms and plasma efavirenz concentrations in HIV-infected adults with CYP2B6 slow metabolizer genotypes. J. Antimicrob. Chemother. 69(8), 2175-2182 (2014
23. Kwara A, Lartey M, Sagoe KW, Kenu E, Court MH. CYP2B6, CYP2A6 and UGT2B7 genetic polymorphisms are predictors of efavirenz mid-dose concentration in HIV-infected patients. AIDS 23(16), 2101-2106 (2009
24. Haas DW, Ribaudo HJ, Kim RB, et al. Pharmacogenetics of efavirenz and central nervous system side effects: An Adult AIDS Clinical Trials Group study. AIDS 18(18), 2391-2400 (2004
25. Tsuchiya K, Gatanaga H, Tachikawa N, et al. Homozygous CYP2B6 6 (Q172H and K262R) correlates with high plasma efavirenz concentrations in HIV-1 patients treated with standard efavirenz-containing regimens. Biochem. Biophys. Res. Commun. 319(4), 1322-1326 (2004
26. Rotger M, Colombo S, Furrer H, et al. Influence of CYP2B6 polymorphism on plasma and intracellular concentrations and toxicity of efavirenz and nevirapine in HIV-infected patients. Pharmacogenet. Genomics 15(1), 1-5 (2005
27. Haas DW, Smeaton LM, Shafer RW, et al. Pharmacogenetics of long-Term responses to antiretroviral regimens containing efavirenz and/or nelfinavir: An Adult AIDS Clinical Trials Group Study. J. Infect. Dis. 192(11), 1931-1942 (2005
28. Rodriguez-Novoa S, Barreiro P, Rendon A, Jimenez-Nacher I, Gonzalez-Lahoz J, Soriano V. Influence of 516GT polymorphisms at the gene encoding the CYP450-2B6 isoenzyme on efavirenz plasma concentrations in HIV-infected subjects. Clin. Infect. Dis. 40(9), 1358-1361 (2005
29. Holzinger ER, Grady B, Ritchie MD, et al. Genome-wide association study of plasma efavirenz pharmacokinetics in AIDS Clinical Trials Group protocols implicates several CYP2B6 variants. Pharmacogenet. Genomics 22(12), 858-867 (2012
30. Wyen C, Hendra H, Vogel M, et al. Impact of CYP2B6 983TC polymorphism on non-nucleoside reverse transcriptase inhibitor plasma concentrations in HIV-infected patients. J. Antimicrob. Chemo. 61(4), 914-918 (2008
31. Wang J, Sonnerborg A, Rane A, et al. Identification of a novel specific CYP2B6 allele in Africans causing impaired metabolism of the HIV drug efavirenz. Pharmacogenet. Genomics 16(3), 191-198 (2006
32. Ribaudo HJ, Liu H, Schwab M, et al. Effect of CYP2B6, ABCB1, and CYP3A5 polymorphisms on efavirenz pharmacokinetics and treatment response: An AIDS Clinical Trials Group study. J. Infect. Dis. 202(5), 717-722 (2010
33. Gounden V, Van Niekerk C, Snyman T, George JA. Presence of the CYP2B6 516 G T polymorphism, increased plasma efavirenz concentrations and early neuropsychiatric side effects in South African HIV-infected patients. AIDS Res. Ther. 7, 32 (2010
34. Sánchez Martín A, Cabrera Figueroa S, Cruz Guerrero R, Hurtado LP, Hurlé AD-G, Carracedo Álvarez Á. Impact of pharmacogenetics on CNS side effects related to efavirenz. Pharmacogenomics 14(10), 1167-1178 (2013
35. Gatanaga H, Hayashida T, Tsuchiya K, et al. Successful efavirenz dose reduction in HIV type 1-infected individuals with cytochrome P450 2B6 6 and 26. Clin. Infect. Dis. 45(9), 1230-1237 (2007
36. Gatanaga H, Oka S. Successful genotype-Tailored treatment with small-dose efavirenz. AIDS 23(3), 433-434 (2009
37. Tsuchiya K, Gatanaga H, Tachikawa N, et al. Homozygous CYP2B6 6 (Q172H and K262R) correlates with high plasma efavirenz concentrations in HIV-1 patients treated with standard efavirenz-containing regimens. Biochem. Biophys. Res. Commun. 319(4), 1322-1326 (2004
38. Penzak SR, Kabuye G, Mugyenyi P, et al. Cytochrome P450 2B6 (CYP2B6) G516T influences nevirapine plasma concentrations in HIV-infected patients in Uganda. HIV Med. 8(2), 86-91 (2007
39. Bertrand J, Chou M, Richardson DM, et al. Multiple genetic variants predict steady-state nevirapine clearance in HIV-infected Cambodians. Pharmacogenet. Genomics 22(12), 868-876 (2012
40. Vardhanabhuti S, Acosta EP, Ribaudo HJ, et al. Clinical and genetic determinants of plasma nevirapine exposure following an intrapartum dose to prevent mother-To-child HIV transmission. J. Infect. Dis. 208(4), 662-671 (2013
41. Colombo S, Soranzo N, Rotger M, et al. Influence of ABCB1, ABCC1, ABCC2, and ABCG2 haplotypes on the cellular exposure of nelfinavir in vivo. Pharmacogenet. Genomics 15(9), 599-608 (2005
42. Saitoh A, Fletcher CV, Brundage R, et al. Efavirenz pharmacokinetics in HIV-1-infected children are associated with CYP2B6-G516T polymorphism. J. Acquir. Immune Defic. Syndr. 45(3), 280-285 (2007
43. Yuan J, Guo S, Hall D, et al. Toxicogenomics of nevirapine-Associated cutaneous and hepatic adverse events among populations of African, Asian, and European Descent. AIDS 25(10), 1271-1280 (2011
44. Hodel EMS, Csajka C, Ariey F, et al. Effect of single nucleotide polymorphisms in cytochrome p450 isoenzyme and N-Acetyltransferase 2 genes on the metabolism of artemisinin-based combination therapies in malaria patients from Cambodia and Tanzania. Antimicrob. Agents Chemother. 57(2), 950-958 (2013
45. Bains RK. African variation at cytochrome P450 genes: Evolutionary aspects and the implications for the treatment of infectious diseases. Evol. Med. Public Health 2013(1), 118-134 (2013
46. Paganotti GM, Gallo BC, Verra F, et al. Human genetic variation is associated with Plasmodium falciparum drug resistance. J. Infect. Dis. 204(11), 1772-1778 ( 2011
47. Parikh S, Ouedraogo J, Goldstein J, Rosenthal P, Kroetz D. Amodiaquine metabolism is impaired by common polymorphisms in CYP2C8: Implications for malaria treatment in Africa. Clin. Pharmacol. Ther. 82(2), 197-203 (2007
48. Adjei GO, Kristensen K, Goka BQ, et al. Effect of concomitant artesunate administration and cytochrome P4502C8 polymorphisms on the pharmacokinetics of amodiaquine in Ghanaian children with uncomplicated malaria. Antimicrob. Agents Chemother. 52(12), 4400-4406 (2008
49. Padol S, Yuan Y, Thabane M, Padol IT, Hunt RH. The effect of CYP2C19 polymorphisms on H. pylori eradication rate in Dual and triple first-line PPI therapies: A meta-Analysis. Am. J. Gastroenterol. 101(7), 1467-1475 (2006
50. Zhao F, Wang J, Yang Y, et al. Effect of CYP2C19 genetic polymorphisms on the efficacy of proton pump inhibitor-based triple therapy for Helicobacter pylori eradication: A meta-Analysis. Helicobacter 13(6), 532-541 (2008
51. Tang H-L, Li Y, Hu Y-F, Xie H-G, Zhai S-D. Effects of CYP2C19 loss-of-function variants on the eradication of H. pylori infection in patients treated with proton pump inhibitor-based triple therapy regimens: A meta-Analysis of randomized clinical trials. PLoS ONE 8(4), e62162 (2013
52. Meletiadis J, Chanock S, Walsh TJ. Defining targets for investigating the pharmacogenomics of adverse drug reactions to antifungal agents. Pharmacogenomics 9(5), 561-584 (2008
53. Levin M-D, den Hollander JG, van Der Holt B, et al. Hepatotoxicity of oral and intravenous voriconazole in relation to cytochrome P450 polymorphisms. J. Antimicrob. Chemother. 60(5), 1104-1107 (2007
54. Matsumoto K, Ikawa K, Abematsu K, et al. Correlation between voriconazole trough plasma concentration and hepatotoxicity in patients with different CYP2C19 genotypes. Int. J. antimicrob. agents 34(1), 91-94 (2009
55. Hariprasad SM, Mieler WF, Holz ER, et al. Determination of vitreous, aqueous, and plasma concentration of orally administered voriconazole in humans. Arch. Ophthalmol. 122(1), 42-47 (2004
56. Scholz I, Oberwittler H, Riedel KD, et al. Pharmacokinetics, metabolism and bioavailability of the triazole antifungal agent voriconazole in relation to CYP2C19 genotype. Br. J. Clin. Pharmacol. 68(6), 906-915 (2009
57. Zonios D, Yamazaki H, Murayama N, et al. Voriconazole metabolism, toxicity, and the effect of cytochrome P450 2C19 genotype. J. Infect. Dis. 209(12), 1941-1948 (2014
58. Kakuda T, Nijs S, van Hoecke G, et al. Pharmacokinetics of etravirine According to CYP2C9 and CYP2C19 metabolizer status: A meta-Analysis of Phase I trials. Presented at: 20th Conference on Retroviruses and Opportunistic Infections. Atlanta, GA, USA, 3-6 March 2013
59. Janha RE, Sisay-Joof F, Hamid-Adiamoh M, et al. Effects of genetic variation at the CYP2C19/CYP2C9 locus on pharmacokinetics of chlorcycloguanil in adult Gambians. Pharmacogenomics 10(9), 1423-1431 (2009
60. Cai Y, Yi J, Zhou C, Shen X. Pharmacogenetic study of drug-metabolising enzyme polymorphisms on the risk of anti-Tuberculosis drug-induced liver injury: A meta-Analysis. PLoS ONE 7(10), e47769 (2012
61. Huang YS, Chern HD, Su WJ, et al. Cytochrome P450 2E1 genotype and the susceptibility to antituberculosis drug-induced hepatitis. Hepatology 37(4), 924-930 (2003
62. Roy PD, Majumder M, Roy B. Pharmacogenomics of anti-TB drugs-related hepatotoxicity. Pharmacogenomics 9(3), 311-321 (2008
63. Roy B, Ghosh SK, Sutradhar D, Sikdar N, Mazumder S, Barman S. Predisposition of antituberculosis drug induced hepatotoxicity by cytochrome P450 2E1 genotype and haplotype in pediatric patients. J. Gastroenterol. Hepatol. 21(4), 784-786 (2006
64. Wang D, Para MF, Koletar SL, Sadee W. Human N-Acetyltransferase 1 (NAT1) 10 and 11 alleles increase protein expression via distinct mechanisms and associate with sulfamethoxazole-induced hypersensitivity. Pharmacogenet. Genomics 21(10), 652-664 (2011
65. Azuma J, Ohno M, Kubota R, et al. NAT2 genotype guided regimen reduces isoniazid-induced liver injury and early treatment failure in the 6-month four-drug standard treatment of tuberculosis: A randomized controlled trial for pharmacogenetics-based therapy. Eur. J. Clin. Pharmacol. 1-11 (2012
66. Sun F, Chen Y, Xiang Y, Zhan S. Drug-metabolising enzyme polymorphisms and predisposition to anti-Tuberculosis drug-induced liver injury: A meta-Analysis. Int. J. Tuberc. Lung Dis. 12(9), 994-1002 (2008
67. Wang P, Xie S, Hao Q, Zhang C, Jiang B. NAT2 polymorphisms and susceptibility to anti-Tuberculosis drug-induced liver injury: A meta-Analysis. Int. J. Tuberc. Lung Dis. 16(5), 589-595 (2012
68. Nebert DW. Polymorphisms in Drug-metabolizing enzymes: What is their clinical relevance and why do they exist? Am. J. Hum. Genetics 60(2), 265-271 (1997
69. Goel U, Bajaj S, Gupta O, Dwivedi N, Dubey A. Isoniazid induced neuropathy in slow versus rapid acetylators: An electrophysiological study. J. Assoc. Phys. India 40(10), 671-672 (1992
70. Yamamoto M, Sobue G, Mukoyama M, Matsuoka Y, Mitsuma T. Demonstration of slow acetylator genotype of N-Acetyltransferase in isoniazid neuropathy using an archival hematoxylin and eosin section of a sural nerve biopsy specimen. J. Neurol. Sci. 135(1), 51-54 (1996
71. Pirmohamed M, Alfirevic A, Vilar J, et al. Association analysis of drug metabolizing enzyme gene polymorphisms in HIV-positive patients with co-Trimoxazole hypersensitivity. Pharmacogenet. Genomics 10(8), 705-713 (2000
72. Huang YS, Su WJ, Huang YH, et al. Genetic polymorphisms of manganese superoxide dismutase, NAD(P)H: Quinone oxidoreductase, glutathione S transferase M1 and T1, and the susceptibility to drug-induced liver injury. J. Hepatol. 47(1), 128-134 (2007
73. Wang D, Curtis A, Papp AC, Koletar SL, Para MF. Polymorphism in glutamate cysteine ligase catalytic subunit (GCLC) is associated with sulfamethoxazole-induced hypersensitivity in HIV/AIDS patients. BMC Med. Genomics 5(1), 32 (2012
74. Rodríguez-Nóvoa S, Martín-Carbonero L, Barreiro P, et al. Genetic factors influencing atazanavir plasma concentrations and the risk of severe hyperbilirubinemia. AIDS 21(1), 41-46 (2007
75. Johnson DH, Venuto C, Ritchie MD, et al. Genomewide association study of atazanavir pharmacokinetics and hyperbilirubinemia in AIDS Clinical Trials Group protocol A5202. Pharmacogenet. Genomics 24(4), 195-203 (2014
76. Lubomirov R, Colombo S, di Iulio J, et al. Association of pharmacogenetic markers with premature discontinuation of first-line anti-HIV therapy: An observational cohort study. J. Infect. Dis. 203(2), 246-257 (2011
77. Ribaudo HJ, Daar ES, Tierney C, et al. Impact of UGT1A1 gilbert variant on Discontinuation of ritonavir-boosted atazanavir in AIDS Clinical Trials Group Study A5202. J. Infect. Dis. 207(3), 420-425 (2013
78. Lankisch TO, Behrens G, Ehmer U, et al. Gilbert's syndrome and hyperbilirubinemia in protease inhibitor therapy - An extended haplotype of genetic variants increases risk in indinavir treatment. J. Hepatol. 50(5), 1010-1018 (2009
79. Cappellini MD, Fiorelli G. Glucose-6-phosphate dehydrogenase deficiency. Lancet 371(9606), 64-74 (2008
80. Toovey S. Mefloquine neurotoxicity: A literature review. Travel Med. Infect. Dis. 7(1), 2-6 (2009
81. Aarnoudse AL, van Schaik RH, Dieleman J, et al. MDR1 gene polymorphisms are associated with neuropsychiatric adverse effects of mefloquine. Clin. Pharmacol. Ther. 80(4), 367-374 (2006
82. Mandíková J, Volková M, Pávek P, et al. Interactions with selected drug renal transporters and transporter-mediated cytotoxicity in antiviral agents from the group of acyclic nucleoside phosphonates. Toxicology 311(3), 135-146 (2013
83. Pushpakom SP, Liptrott NJ, Rodríguez-Nóvoa S, et al. Genetic variants of ABCC10, a novel tenofovir transporter, are associated with kidney tubular dysfunction. J. Infect. Dis. 204(1), 145-153 (2011
84. Kohler JJ, Hosseini SH, Green E, et al. Tenofovir renal proximal tubular toxicity is regulated by OAT1 and MRP4 transporters. Lab. Invest 91(6), 852-858 (2011
85. Rodriguez-Novoa S, Labarga P, Soriano V. Pharmacogenetics of tenofovir treatment. Pharmacogenomics 10(10), 1675-1685 (2009
86. Lebrecht D, Venhoff AC, Kirschner J, Wiech T, Venhoff N, Walker UA. Mitochondrial tubulopathy in tenofovir disoproxil fumarate-Treated rats. J. Acquir. Immune Defic. Syndr. 51(3), 258-263 (2009
87. Rodríguez-Nóvoa S, Labarga P, Soriano V, et al. Predictors of kidney tubular dysfunction in HIV-infected patients treated with tenofovir: A pharmacogenetic study. Clin. Infect. Dis. 48(11), e108-e116 (2009
88. Kiser JJ, Aquilante CL, Anderson PL, King TM, Carten ML, Fletcher CV. Clinical and genetic determinants of intracellular tenofovir diphosphate concentrations in HIV-infected patients. J. Acquir. Immune Defic. Syndr. 47(3), 298-303 (2008
89. Uwai Y, Ida H, Tsuji Y, Katsura T, Inui K-I. Renal transport of adefovir, cidofovir, and tenofovir by SLC22A family members (hOAT1, hOAT3, and hOCT2). Pharm. Res. 24(4), 811-815 (2007
90. Izzedine H, Hulot J-S, Villard E, et al. Association between ABCC2 gene haplotypes and tenofovir-induced proximal tubulopathy. J. Infect. Dis. 194(11), 1481-1491 (2006
91. Ray AS, Cihlar T, Robinson KL, et al. Mechanism of active renal tubular efflux of tenofovir. Antimicrob. Agents Chemother. 50(10), 3297-3304 (2006
92. Suppiah V, Moldovan M, Ahlenstiel G, et al. IL28B is associated with response to chronic hepatitis C interferon-A and ribavirin therapy. Nat. Genet. 41(10), 1100-1104 (2009
93. Ge D, Fellay J, Thompson AJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 461(7262), 399-401 (2009
94. Rauch A, Kutalik Z, Descombes P, et al. Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure:a genome-wide association study. Gastroenterology 138(4), 1338-1345, 1345.e1-7 (2010
95. Bibert S, Roger T, Calandra T, et al. IL28B expression Depends on a novel TT/-G polymorphism which improves HCV clearance prediction. J. Exp. Med. 210(6), 1109-1116 (2013
96. Fellay J, Thompson AJ, Ge D, et al. ITPA Gene Variants Protect Against Anaemia in Patients Treated for Chronic Hepatitis C. Nature 464(7287), 405-408 (2010
97. Thompson AJ, Fellay J, Patel K, et al. Variants in the ITPA gene protect against ribavirin-induced hemolytic anemia and decrease the need for ribavirin Dose reduction. Gastroenterology 139(4), 1181-1189 (2010
98. Sakamoto N, Tanaka Y, Nakagawa M, et al. ITPA gene variant protects against anemia induced by pegylated interferon-A and ribavirin therapy for Japanese patients with chronic hepatitis C. Hepatol. Res. 40(11), 1063-1071 (2010
99. Hitomi Y, Cirulli ET, Fellay J, et al. Inosine triphosphate protects against ribavirin-induced adenosine triphosphate loss by adenylosuccinate synthase function. Gastroenterology 140(4), 1314-1321 (2011
100. Clark P, Aghemo A, Degasperi E, et al. Inosine triphosphatase deficiency helps predict anaemia, anaemia management and response in chronic hepatitis C therapy. J. Viral Hepat. 20(12), 858-866 (2013
101. Rallón NI, Morello J, Labarga P, et al. Impact of inosine triphosphatase gene variants on the risk of anemia in HIV/hepatitis C virus-coinfected patients treated for chronic hepatitis C. Clin. Infect. Dis. 53(12), 1291-1295 (2011
102. Whirl-Carrillo M, McDonagh E, Hebert J, et al. Pharmacogenomics knowledge for personalized medicine. Clin. Pharmacol. Ther. 92(4), 414-417 (2012
103. Hautekeete ML, Horsmans Y, van Waeyenberge C, et al. HLA association of amoxicillin-clavulanate-induced hepatitis. Gastroenterology 117(5), 1181-1186 (1999
104. Lucena MI, Molokhia M, Shen Y, et al. Susceptibility to amoxicillin-clavulanate-induced liver injury is influenced by multiple HLA class I and II alleles. Gastroenterology 141(1), 338-347 (2011
105. Donaldson PT, Daly AK, Henderson J, et al. Human leucocyte antigen class II genotype in susceptibility and resistance to co-Amoxiclav-induced liver injury. J. Hepatol. 53(6), 1049-1053 (2010
106. O'Donohue J, Oien K, Donaldson P, et al. Co-Amoxiclav jaundice: Clinical and histological features and HLA class II association. Gut 47(5), 717-720 (2000
107. Stephens C, López-Nevot M-Á, Ruiz-Cabello F, et al. HLA alleles influence the clinical signature of amoxicillin-clavulanate hepatotoxicity. PLoS ONE 8(7), e68111 (2013
108. Zhang F-R, Liu H, Irwanto A, et al. HLA-B 13:01 and the dapsone hypersensitivity syndrome. N. Engl. J. Med. 369(17), 1620-1628 (2013
109. Wang H, Yan L, Zhang G, et al. Association between HLA-B 1301 and dapsone-induced hypersensitivity reactions among leprosy patients in China. J. Invest. Dermatol. 133(11), 2642-2644 (2013
110. Daly AK, Donaldson PT, Bhatnagar P, et al. HLA-B.5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin. Nat. Genet. 41(7), 816-819 (2009
111. Hetherington S, Hughes AR, Mosteller M, et al. Genetic variations in HLA-B region and hypersensitivity reactions to abacavir. Lancet 359(9312), 1121-1122 (2002
112. Mallal S, Nolan D, Witt C, et al. Association between presence of HLA-B.5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-Transcriptase inhibitor abacavir. Lancet 359(9308), 727-732 (2002
113. Saag M, Balu R, Phillips E, et al. High sensitivity of human leukocyte antigen-B.5701 as a marker for immunologically confirmed abacavir hypersensitivity in white and black patients. Clin. Infect. Dis. 46(7), 1111-1118 (2008
114. Martin AM, Nolan D, James I, et al. Predisposition to nevirapine hypersensitivity associated with HLA-DRB1 0101 and abrogated by low CD4 T-cell counts. AIDS 19(1), 97-99 (2005
115. Chantarangsu S, Mushiroda T, Mahasirimongkol S, et al. Genome-wide association study identifies variations in 6p21.3 associated with nevirapine-induced rash. Clin. Infect. Dis. 53(4), 341-348 (2011
116. Gatanaga H, Yazaki H, Tanuma J, et al. HLA-Cw8 primarily associated with hypersensitivity to nevirapine. AIDS 21(2), 264-265 (2007
117. Keane NM, Pavlos RK, McKinnon E, et al. HLA class I restricted CD8+ and Class II restricted CD4+ T cells are implicated in the pathogenesis of nevirapine hypersensitivity. AIDS 500, 14-00302 (2014
118. Littera R, Carcassi C, Masala A, et al. HLA-dependent hypersensitivity to nevirapine in Sardinian HIV patients. AIDS 20(12), 1621-1626 (2006
119. Gao S, Gui X-E, Liang K, Liu Z, Hu J, Dong B. HLA-dependent hypersensitivity reaction to nevirapine in Chinese Han HIV-infected patients. AIDS Res. Hum. Retroviruses 28(6), 540-543 (2012
120. Phillips E, Bartlett JA, Sanne I, et al. Associations between HLA-DRB1.0102, HLA-B.5801, and hepatotoxicity during initiation of nevirapine-containing regimens in South Africa. J. AIDS 62(2), e55-e57 (2013
121. Chantarangsu S, Mushiroda T, Mahasirimongkol S, et al. HLA-B.3505 allele is a strong predictor for nevirapine-induced skin adverse drug reactions in HIV-infected Thai patients. Pharmacogenet. Genomics 19(2), 139-146 (2009
122. Yuan J, Guo S, Hall D, et al. Toxicogenomics of nevirapine-Associated cutaneous and hepatic adverse events among populations of African, Asian, and European Descent. AIDS 25(10), 1271-1280 (2011
123. Carr DF, Chaponda M, Jorgensen AL, et al. Association of human leukocyte antigen alleles and nevirapine hypersensitivity in a Malawian HIV-infected population. Clin. Infect. Dis. 56(9), 1330-1339 (2013
124. Fischel-Ghodsian N. Genetic factors in aminoglycoside toxicity. Pharmacogenomics 6(1), 27-36 (2005
125. Guan M-X. Mitochondrial 12S rRNA mutations associated with aminoglycoside ototoxicity. Mitochondrion 11(2), 237-245 (2011
126. Pacheu-Grau D, Gómez-Durán A, Montoya J, Ruiz-Pesini E. Influence of mtDNA genetic variation on antibiotic therapy. Pharmacogenomics 11(9), 1185-1187 (2010
127. Prezant TR, Agapian JV, Bohlman MC, et al. Mitochondrial ribosomal RNA mutation associated with both antibiotic-induced and non-syndromic deafness. Nat. Genet. 4(3), 289-294 (1993
128. Carson J, Cerda J, Chae JH, Hirano M, Maggiore P. Severe lactic acidosis associated with linezolid use in a patient with the mitochondrial DNA A2706G polymorphism. Pharmacotherapy 27(5), 771-774 (2007
129. Holzinger ER, Hulgan T, Ellis RJ, et al. Mitochondrial DNA variation and HIV-Associated sensory neuropathy in CHARTER. J. Neurovirol. 18(6), 511-520 (2012
130. Canter JA, Robbins GK, Selph D, et al. African mitochondrial DNA subhaplogroups and peripheral neuropathy during antiretroviral therapy. J. Infect. Dis. 201(11), 1703-1707 (2010
131. Sinxadi PZ, Dave JA, Samuels DC, et al. Mitochondrial genomics and antiretroviral therapy-Associated metabolic complications in HIV-infected black South Africans: A pilot study. AIDS Res. Hum. Retroviruses 29(7), 1031-1039 (2013
132. Kampira E, Kumwenda J, van Oosterhout JJ, Dandara C. Mitochondrial DNA subhaplogroups L0a2 and L2a modify susceptibility to peripheral neuropathy in Malawian adults on stavudine containing highly active antiretroviral therapy. J. Acquir. Immune Defic. Syndr. 63(5), 647-652 (2013
133. De Luca A, Nasi M, Di Giambenedetto S, et al. Mitochondrial DNA haplogroups and incidence of lipodystrophy in HIV-infected patients on long-Term antiretroviral therapy. J. Acquir. Immune Defic. Syndr. 59(2), 113-120 (2012
134. Hulgan T, Haubrich R, Riddler SA, et al. European mitochondrial DNA haplogroups and metabolic changes during antiretroviral therapy in AIDS Clinical Trials Group Study A5142. AIDS 25(1), 37-47 (2011
135. Hendrickson SL, Kingsley LA, Ruiz-Pesini E, et al. Mitochondrial DNA haplogroups influence lipoatrophy after highly active anti-retroviral therapy. J. Acquir. Immune Defic. Syndr. 51(2), 111-116 (2009
136. Micheloud D, Berenguer J, Guzmán-Fulgencio M, et al. European mitochondrial DNA haplogroups and metabolic disorders in HIV/HCV-coinfected patients on highly active antiretroviral therapy. J. Acquir. Immune Defic. Syndr. 58(4), 371-378 (2011
137. Hulgan T, Stein JH, Cotter BR, et al. Mitochondrial DNA variation and changes in adiponectin and endothelial function in HIV-infected adults after antiretroviral therapy initiation. AIDS Res. Hum. Retroviruses 29(10), 1293-1299 (2013
138. Canter J, Haas D, Kallianpur A, et al. The mitochondrial pharmacogenomics of haplogroup T: MTND2 LHON4917G and antiretroviral therapy-Associated peripheral neuropathy. Pharmacogenomics J. 8(1), 71-77 (2007
139. Hulgan T, Haas DW, Haines JL, et al. Mitochondrial haplogroups and peripheral neuropathy during antiretroviral therapy: An adult AIDS clinical trials group study. AIDS 19(13), 1341-1349 (2005
140. Hendrickson SL, Jabs DA, Van Natta M, Lewis RA, Wallace DC, O'Brien SJ. Mitochondrial haplogroups are associated with risk of neuroretinal disorder in HIV-positive patients. J. Acquir. Immune Defic. Syndr. 53(4), 451-455 (2010
141. Andrade RJ, Lucena MI, Fernández MC, et al. Drug-induced liver injury: An analysis of 461 incidences submitted to the Spanish registry over a 10-year period. Gastroenterology 129(2), 512-521 (2005
142. Stricker B, Van Den Broek J, Keuning J, et al. Cholestatic hepatitis due to antibacterial combination of amoxicillin and clavulanic acid (augmentin). Digest. Dis. Sci. 34(10), 1576-1580 (1989
143. Lucena MI, Andrade RJ, Fernández MC, et al. Determinants of the clinical expression of amoxicillin-clavulanate hepatotoxicity: A prospective series from Spain. Hepatology 44(4), 850-856 (2006
144. Russmann S, Kaye JA, Jick SS, Jick H. Risk of cholestatic liver disease associated with flucloxacillin and flucloxacillin prescribing habits in the UK: Cohort study using data from the UK General Practice Research Database. Br. J. Clin. Pharmacol. 60(1), 76-82 (2005
145. Monshi MM, Faulkner L, Gibson A, et al. Human leukocyte antigen HLA-B.57:01 restricted activation of drug-specific T cells provides the immunological basis for flucloxacillin-induced liver injury. Hepatology 57(2), 727-739 (2013
146. Wuillemin N, Adam J, Fontana S, Krähenbühl S, Pichler WJ, Yerly D. HLA haplotype determines hapten or pi T cell reactivity to flucloxacillin. J. Immunol. 190(10), 4956-4964 (2013
147. Becquemont L, Alfirevic A, Amstutz U, et al. Practical recommendations for pharmacogenomics-based prescription: 2010 ESF-UB Conference on Pharmacogenetics and pharmacogenomics. Pharmacogenomics 12(1), 113-124 (2011
148. Hagymási K, Müllner K, Herszényi L, Tulassay Z. Update on the pharmacogenomics of proton pump inhibitors. Pharmacogenomics 12(6), 873-888 (2011
149. Suzuki H, Nishizawa T, Hibi T. Helicobacter pylori eradication therapy. Future Microbiol. 5(4), 639-648 (2010
150. Horn J. Review article: Relationship between the metabolism and efficacy of proton pump inhibitors - focus on rabeprazole. Aliment. Pharmacol. Ther. 20(S6), 11-19 (2004
151. Andersson T, Röhss K, Bredberg E, Hassan-Alin M. Pharmacokinetics and pharmacodynamics of esomeprazole, the S-isomer of omeprazole. Aliment. Pharmacol. Ther. 15(10), 1563-1569 (2001
152. Li WPA, Girard T, Farndon P, Cooley C, Lithgow J. Pharmacogenetics of CYP2C19: Functional and clinical implications of a new variant CYP2C19 17. Br. J. Clin. Pharmacol. 69(3), 222-230 (2010
153. Zanger UM, Turpeinen M, Klein K, Schwab M. Functional pharmacogenetics/genomics of human cytochromes P450 involved in Drug biotransformation. Anal. Bioanal. Chem. 392(6), 1093-1108 (2008
154. Bertilsson L. Geographical/interracial differences in polymorphic drug oxidation. Clin. Pharmacokinet. 29(3), 192-209 (1995
155. Guthrie O. Aminoglycoside induced ototoxicity. Toxicology 249(2-3), 91-96 (2008
156. Selimoglu E. Aminoglycoside-induced ototoxicity. Curr. Pharm. Des. 13(1), 119-126 (2007
157. Xie J, Talaska AE, Schacht J. New developments in aminoglycoside therapy and ototoxicity. Hear. Res. 281(1), 28-37 (2011
158. Pacheu-Grau D, Gómez-Durán A, Iglesias E, López- Gallardo E, Montoya J, Ruiz-Pesini E. Mitochondrial antibiograms in personalized medicine. Hum. Mol. Genet. 22(6), 1132-1139 (2013
159. Garrabou G, Soriano A, López S, et al. Reversible inhibition of mitochondrial protein synthesis during linezolid-related hyperlactatemia. Antimicrob. Agents Chemother. 51(3), 962-967 (2007
160. McKee E, Ferguson M, Bentley A, Marks T. Inhibition of mammalian mitochondrial protein synthesis by oxazolidinones. Antimicrob. Agents Chemother. 50(6), 2042-2049 (2006
161. De Vriese AS, Van Coster R, Smet J, et al. Linezolid-induced inhibition of mitochondrial protein synthesis. Clin. Infect. Dis. 42(8), 1111-1117 (2006
162. Soriano A, Miró O, Mensa J. Mitochondrial toxicity associated with linezolid. N. Engl. J. Med. 353(21), 2305-2306 (2005
163. Jaffe H, Ammann A, Abrams D, Lewis B, Golden J. Complications of co-Trimoxazole in treatment of AIDS-Associated Pneumocystis carinii pneumonia in homosexual men. Lancet 322(8359), 1109-1111 (1983
164. Leoung GS, Stanford JF, Giordano MF, et al. Trimethoprim-sulfamethoxazole (TMP-SMZ) dose escalation versus direct rechallenge for Pneumocystis carinii pneumonia prophylaxis in human immunodeficiency virus-infected patients with previous adverse reaction to TMP-SMZ. J. Infect. Dis. 184(8), 992-997 (2001
165. Lin D, Li W, Rieder M. Cotrimoxazole for prophylaxis or treatment of opportunistic infections of HIV/AIDS in patients with previous history of hypersensitivity to cotrimoxazole. Cochrane Database Syst. Rev. 2, 1-15 (2007
166. Tilles SA. Practical issues in the management of hypersensitivity reactions: Sulfonamides. South. Med. J. 94(8), 817-824 (2001
167. Alfirevic A, Vilar FJ, Alsbou M, et al. TNF, LTA, HSPA1L and HLA-DR gene polymorphisms in HIV-positive patients with hypersensitivity to cotrimoxazole. Pharmacogenomics 10(4), 531-540 (2009
168. Watkins S, Pichler WJ. Sulfamethoxazole Induces a switch mechanism in T cell receptors containing TCRVβ20-1, altering pHLA recognition. PLoS ONE 8(10), e76211 (2013
169. Bukirwa H, Garner P, Critchley J. Chlorproguanil- dapsone for treating uncomplicated malaria. Cochrane Database Syst. Rev. 4, CD004387 (2004
170. Fanello CI, Karema C, Avellino P, et al. High risk of severe anaemia after chlorproguanil-dapsone+ artesunate antimalarial treatment in patients with G6PD (A-) deficiency. PLoS ONE 3(12), e4031 (2008
171. Premji Z, Umeh RE, Owusu-Agyei S, et al. Chlorproguanil-dapsone-Artesunate versus artemether- lumefantrine: A randomized, double-blind Phase III trial in African children and adolescents with uncomplicated Plasmodium falciparum malaria. PLoS ONE 4(8), e6682 (2009
172. Luzzatto L. The rise and fall of the antimalarial Lapdap: A lesson in pharmacogenetics. Lancet 376(9742), 739-741 (2010
173. Lorenz M, Wozel G, Schmitt J. Hypersensitivity reactions to dapsone: A systematic review. Acta Derm. Venereol. 92(2), 194-199 (2012
174. Ramachandran G, Swaminathan S. Role of pharmacogenomics in the treatment of tuberculosis: A review. Pharmacogenomics Personal. Med. 5, 89-98 (2012
175. Monteiro T, El-Jaick K, Jeovanio-Silva A, et al. The roles of GSTM1 and GSTT1 null genotypes and other predictors in anti-Tuberculosis drug-induced liver injury. J. Clin. Pharm. Ther. 37(6), 712-718 (2012
176. Kim S-H, Kim S-H, Bahn J-W, et al. Genetic polymorphisms of drug-metabolizing enzymes and anti-TB drug-induced hepatitis. Pharmacogenomics 10(11), 1767-1779 (2009
177. Vuilleumier N, Rossier MF, Chiappe A, et al. CYP2E1 genotype and isoniazid-induced hepatotoxicity in patients treated for latent tuberculosis. Eur. J. Clin. Pharmacol. 62(6), 423-429 (2006
178. Cho H-J, Koh W-J, Ryu Y-J, et al. Genetic polymorphisms of NAT2 and CYP2E1 associated with antituberculosis drug-induced hepatotoxicity in Korean patients with pulmonary tuberculosis. Tuberculosis 87(6), 551-556 (2007
179. Yamada S, Tang M, Richardson K, et al. Genetic variations of NAT2 and CYP2E1 and isoniazid hepatotoxicity in a diverse population. Pharmacogenomics 10(9), 1433-1445 (2009
180. Yamada S, Richardson K, Tang M, et al. Genetic variation in carboxylesterase genes and susceptibility to isoniazid-induced hepatotoxicity. Pharmacogenomics J. 10(6), 524-536 (2010
181. Sharma SK, Balamurugan A, Saha PK, Pandey RM, Mehra NK. Evaluation of clinical and immunogenetic risk factors for the development of hepatotoxicity during antituberculosis treatment. Am. J. Respir. Crit. Care Med. 166(7), 916-919 (2002
182. Kim SH, Kim SH, Yoon HJ, et al. TNF-A genetic polymorphism -308G/A and antituberculosis drug-induced hepatitis. Liver Int. 32(5), 809-814 (2012
183. Yimer G, Ueda N, Habtewold A, et al. Pharmacogeneticand pharmacokinetic biomarker for efavirenz based ARV and rifampicin based anti-TB drug induced liver injury in TB-HIV infected patients. PLoS ONE 6(12), e27810 (2011
184. Tang S, Lv X, Zhang Y, et al. Cytochrome P450 2E1 gene polymorphisms/haplotypes and anti-Tuberculosis drug-induced hepatitis in a Chinese cohort. PLoS ONE 8(2), e57526 (2013
185. Mikus G, Schöwel V, Drzewinska M, et al. Potent cytochrome P450 2C19 genotype-related interaction between voriconazole and the cytochrome P450 3A4 inhibitor ritonavir. Clin. Pharmacol. Ther. 80(2), 126-135 (2006
186. Mikus G, Scholz IM, Weiss J. Pharmacogenomics of the triazole antifungal agent voriconazole. Pharmacogenomics 12(6), 861-872 (2011
187. Hicks JK, Crews KR, Flynn P, et al. Voriconazole plasma concentrations in immunocompromised pediatric patients vary by CYP2C19 diplotypes. Pharmacogenomics 15(8), 1065-1078 (2014
188. Suzuki Y, Tokimatsu I, Sato Y, et al. Association of sustained high plasma trough concentration of voriconazole with the incidence of hepatotoxicity. Clin. Chim. Acta 424, 119-122 (2013
189. Laties AM, Zrenner E. Viagrå (sildenafil citrate) and ophthalmology. Prog. Retin. Eye Res. 21(5), 485-506 (2002
190. WHO. Guidelines for the treatment of malaria (2006). www.who.int/malaria/publications/atoz/9789241547925/en/
191. Di YM, Chow VD-W, Yang L-P, Zhou S-F. Structure, function, regulation and polymorphism of human cytochrome P450 2A6. Curr. Drug Metabol. 10(7), 754-780 (2009
192. Zanger UM, Schwab M. Cytochrome P450 enzymes in Drug metabolism: Regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol. Ther. 138(1), 103-141 (2013
193. Aweeka FT, German PI. Clinical pharmacology of artemisinin-based combination therapies. Clin. Pharmacokinet. 47(2), 91-102 (2008
194. Coto-Llerena M, Pérez-del-Pulgar S, Crespo G, et al. Donor and recipient IL28B polymorphisms in HCV-infected patients undergoing antiviral therapy before and after liver transplantation. Am. J. Transplant. 11(5), 1051-1057 (2011
195. Charlton MR, Thompson A, Veldt BJ, et al. Interleukin-28B polymorphisms are associated with histological recurrence and treatment response following liver transplantation in patients with hepatitis C virus infection. Hepatology 53(1), 317-324 (2011
196. Fukuhara T, Taketomi A, Motomura T, et al Variants in IL28B in liver recipients and donors correlate with response to Peg-interferon and ribavirin therapy for recurrent hepatitis C. Gastroenterology 139(5), 1577-1585, 1585.e1-3 (2010
197. Rallón NI, Soriano V, Naggie S, et al. IL28B gene polymorphisms and viral kinetics in HIV/hepatitis C virus-coinfected patients treated with pegylated interferon and ribavirin. AIDS 25(8), 1025-1033 (2011
198. Suppiah V, Gaudieri S, Armstrong NJ, et al. IL28B, HLA-C, and KIR variants additively predict response to therapy in chronic hepatitis C virus infection in a European Cohort: A cross-sectional study. PLoS Med. 8(9), e1001092 (2011
199. Nozawa Y, Umemura T, Joshita S, et al. KIR, HLA, and IL28B variant predict response to antiviral therapy in genotype 1 chronic hepatitis C patients in Japan. PLoS ONE 8(12), e83381 (2013
200. Prokunina-Olsson L, Muchmore B, Tang W, et al. A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus. Nat. Genet. 45(2), 164-171 (2013
201. Amanzada A, Kopp W, Spengler U, Ramadori G, Mihm S. Interferon-?4 (IFNL4) transcript expression in human liver tissue samples. PLoS ONE 8(12), e84026 (2013
202. Franco S, Aparicio E, Parera M, Clotet B, Tural C, Martinez MA. IFNL4 ss469415590 variant is a better predictor than ILF3 (IL28B) rs12979860 of pegylated interferon-Alpha/ribavirin therapy failure in hepatitis C virus/HIV-1 coinfected patients. AIDS 28(1), 133-136 (2013
203. Hamming OJ, Terczyńska-Dyla E, Vieyres G, et al. Interferon lambda 4 signals via the IFN? receptor to regulate antiviral activity against HCV and coronaviruses. EMBO J. 32(23), 3055-3065 (2013
204. Kamal SM. Pharmacogenetics of hepatitis C: Transition from interferon-based therapies to direct-Acting antiviral agents. Hepat. Med. 6, 61 (2014
205. Muir AJ, Gong L, Johnson SG, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for IFNL3 (IL28B) genotype and PEG interferon- A-based regimens. Clin. Pharmacol. Ther. 95(2), 141-146 (2013
206. Symonds W, Cutrell A, Edwards M, et al. Risk factor analysis of hypersensitivity reactions to abacavir. Clin. Ther. 24(4), 565-573 (2002
207. Aboulker J, Babiker A, Campagnucci A, et al. Comparison of dual nucleoside-Analogue reverse-Transcriptase inhibitor regimens with and without nelfinavir in children with HIV-1 who have not previously been treated: The PENTA 5 randomised trial. Lancet 359(9308), 733-740 (2002
208. Martin AM, Nolan D, Gaudieri S, et al. Predisposition to abacavir hypersensitivity conferred by HLA-B.5701 and a haplotypic Hsp70-Hom variant. Proc. Natl Acad. Sci. USA 101(12), 4180-4185 (2004
209. Phillips EJ, Wong GA, Kaul R, et al. Clinical and immunogenetic correlates of abacavir hypersensitivity. AIDS 19(9), 979-981 (2005
210. Mallal S, Phillips E, Carosi G, et al. HLA-B.5701 screening for hypersensitivity to abacavir. N. Engl. J. Med. 358(6), 568-579 (2008
211. Phillips E, Mallal S. Successful translation of pharmacogenetics into the clinic. Mol. Diagn. Ther. 13(1), 1-9 (2009
212. Kis O, Zastre JA, Hoque MT, Walmsley SL, Bendayan R. Role of drug efflux and uptake transporters in atazanavir intestinal permeability and drug-drug interactions. Pharm. Res. 1-15 (2012
213. Moss DM, San Kwan W, Liptrott NJ, et al. Raltegravir is a substrate for SLC22A6: A putative mechanism for the interaction between raltegravir and tenofovir. Antimicrob. Agents Chemother. 55(2), 879-887 (2011
214. Nicol MR, Fedoriw Y, Mathews M, et al. Expression of six drug transporters in vaginal, cervical, and colorectal tissues: Implications for drug disposition in HIV prevention. J. Clin. Pharmacol. 54(5), 574-583 (2014
215. Ruane P, Dejesus E, Berger D, et al. Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of tenofovir alafenamide (TAF) as 10-day monotherapy in HIV-1-positive adults. J. Acquir. Immune Defic. Syndr. 63(4), 449-455 (2013
216. Ortiz M, Poloni ES, Furrer H, et al. No longitudinal mitochondrial DNA sequence changes in HIV-infected individuals with and without lipoatrophy. J. Infect. Dis. 203(5), 620-624 (2011
217. Nasi M, Guaraldi G, Orlando G, et al. Mitochondrial DNA haplogroups and highly active antiretroviral therapy-related lipodystrophy. Clin. Infect. Dis. 47(7), 962-968 (2008
218. Hulgan T, Tebas P, Canter JA, et al. Hemochromatosis gene polymorphisms, mitochondrial haplogroups, and peripheral lipoatrophy during antiretroviral therapy. J. Infect. Dis. 197(6), 858-866 (2008
219. Kallianpur AR, Hulgan T, Canter JA, et al. Hemochromatosis (HFE) gene mutations and peripheral neuropathy during antiretroviral therapy. AIDS 20(11), 1503-1513 (2006
220. Hulgan T, Hughes M, Sun X, et al. Oxidant stress and peripheral neuropathy during antiretroviral therapy: An AIDS clinical trials group study. J. Acquir. Immune Defic. Syndr. 42(4), 450-454 (2006
221. Wester CW, Eden SK, Shepherd BE, et al. Risk factors for symptomatic hyperlactatemia and lactic acidosis among combination antiretroviral therapy-Treated adults in Botswana: Results from a clinical trial. AIDS Res. Hum. Retroviruses 28(8), 759-765 (2012
222. Leung GP. Iatrogenic mitochondriopathies: A recent lesson from nucleoside/nucleotide reverse transcriptase inhibitors. Adv. Exp. Med. Biol. 942 347-369 (2012
223. Arenas-Pinto A, Weller I, Ekong R, et al. Common inherited mitochondrial DNA mutations and nucleoside reverse transcriptase inhibitor-induced severe hyperlactataemia in HIV-infected adults: An exploratory study. Antiviral Ther. 17(2), 275-282 (2012
224. Feeney E, Chazallon C, O'Brien N, et al. Hyperlactataemia in HIV-infected subjects initiating antiretroviral therapy in a large randomized study (a substudy of the INITIO trial). HIV Med. 12(10), 602-609 (2011
225. Matthews LT, Giddy J, Ghebremichael M, et al. A risk-factor guided approach to reducing lactic acidosis and hyperlactatemia in patients on antiretroviral therapy. PLoS ONE 6(4), e18736 (2011
226. Fielder J, Rambiki K. Occurrence of stavudine-induced lactic acidosis in 3 members of an African family. J. Int. Assoc. Phys. AIDS Care 9(4), 236-239 (2010
227. Thoden J, Lebrecht D, Venhoff N, Neumann J, Müller K, Walker UA. Highly active antiretroviral HIV therapy-Associated fatal lactic acidosis: Quantitative and qualitative mitochondrial DNA lesions with mitochondrial dysfunction in multiple organs. AIDS 22(9), 1093-1094 (2008
228. Wester CW, Okezie OA, Thomas AM, et al. Higher-Than-expected rates of lactic acidosis among highly active antiretroviral therapy-Treated women in Botswana: Preliminary results from a large randomized clinical trial. J. Acquir. Immune Defic. Syndr. 46(3), 318-322 (2007
229. Kallianpur AR, Hulgan T. Pharmacogenetics of nucleoside reverse-Transcriptase inhibitor-Associated peripheral neuropathy. Pharmacogenomics 10(4), 623-637 (2009
230. Kampira E, Kumwenda J, Van Oosterhout JJ, Dandara C. Mitochondrial subhaplogroups and differential risk of stavudine-induced lipodystrophy in Malawian HIV/AIDS patients. Pharmacogenomics 14(16), 1999-2004 (2013
231. Ward BA, Gorski JC, Jones DR, Hall SD, Flockhart DA, Desta Z. The cytochrome P450 2B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: Implication for HIV/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity. J. Pharmacol. Exp. Ther. 306(1), 287-300 (2003
232. Riska P, Lamson M, MacGregor T, et al. Disposition and biotransformation of the antiretroviral drug nevirapine in humans. Drug Metab. Dispos. 27(8), 895-901 (1999
233. Belanger AS, Caron P, Harvey M, Zimmerman PA, Mehlotra RK, Guillemette C. Glucuronidation of the antiretroviral drug efavirenz by UGT2B7 and an in vitro investigation of drug-drug interaction with zidovudine. Drug Metab. Dispos. 37(9), 1793-1796 (2009
234. Kwara A, Lartey M, Sagoe KW, Rzek NL, Court MH. CYP2B6 (c.516G-T) and CYP2A6 (9B and/or 17) polymorphisms are independent predictors of efavirenz plasma concentrations in HIV-infected patients. Br. J. Clin. Pharmacol. 67(4), 427-436 (2009
235. Gutierrez F, Navarro A, Padilla S, et al. Prediction of neuropsychiatric adverse events associated with long-Term efavirenz therapy, using plasma drug level monitoring. Clin. Infect. Dis. 41(11), 1648-1653 (2005
236. Gounden V, van Niekerk C, Snyman T, George JA. Presence of the CYP2B6 516G T polymorphism, increased plasma efavirenz concentrations and early neuropsychiatric side effects in South African HIV-infected patients. AIDS Res. Ther. 7, 32 (2010
237. Clifford DB, Evans S, Yang Y, et al. Impact of efavirenz on neuropsychological performance and symptoms in HIV-infected individuals. Ann. Intern. Med. 143(10), 714-721 (2005
238. Marzolini C, Telenti A, Decosterd LA, Greub G, Biollaz J, Buclin. T. Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1- infected patients. AIDS 15(1), 71-75 (2001
239. Gallego L, Barreiro P, del Rio R, et al. Analyzing sleep abnormalities in HIV-infected patients treated with efavirenz. Clin. Infect. Dis. 38(3), 430-432 (2004
240. Read TR, Carey D, Mallon P, et al. Efavirenz plasma concentrations did not predict cessation of therapy due to neuropsychiatric symptoms in a large randomized trial. AIDS 23(16), 2222-2223 (2009
241. Takahashi M, Ibe S, Kudaka Y, et al. No observable correlation between central nervous system side effects and EFV plasma concentrations in Japanese HIV type 1-infected patients treated with EFV containing HAART. AIDS Res. Hum. Retroviruses 23(8), 983-987 (2007
242. Fumaz CR, Munoz-Moreno JA, Molto J, et al. Long-Term neuropsychiatric disorders on efavirenz-based approaches: Quality of life, psychologic issues, and adherence. J. Acquir. Immune Defic. Syndr. 38(5), 560-565 (2005
243. Gatanaga H, Hayashida T, Tsuchiya K, et al. Successful efavirenz dose reduction in HIV type 1-infected individuals with cytochrome P450 2B6 6 and 26. Clin. Infect. Dis. 45(9), 1230-1237 (2007
244. Haas DW, Severe P, Juste MAJ, Pape JW, Fitzgerald DW. Functional CYP2B6 variants and virologic response to an efavirenz-containing regimen in Port-Au-Prince, Haiti. J. Antimicrob. Chemo. 69(8), 2187-2190 (2014
245. Puls R, Group tES. A daily dose of 400mg efavirenz (EFV) is non-inferior to the standard 600mg dose: Week 48 data from the ENCORE1 study, a randomised, double-blind, placebo controlled, non-inferiority trial. Presented at: 7th IAS Conference on HIV Pathogenesis, Treatment and Prevention, Kuala Lumpur, Malaysia, 30 June-3 July 2013 (Abstract WELBB01
246. Sanne I, Mommeja-Marin H, Hinkle J, et al. Severe hepatotoxicity associated with nevirapine use in HIV-infected subjects. J. Infect. Dis. 191(6), 825-829 (2005
247. Uttayamakul S, Likanonsakul S, Manosuthi W, et al. Effects of CYP2B6 G516T polymorphisms on plasma efavirenz and nevirapine levels when co-Administered with rifampicin in HIV/TB co-infected Thai adults. AIDS Res. Ther. 7, 8 (2010
248. Ramachandran G, Ramesh K, Hemanth Kumar AK, et al. Association of high T allele frequency of CYP2B6 G516T polymorphism among ethnic south Indian HIV-infected patients with elevated plasma efavirenz and nevirapine. J. Antimicrob. Chemother. 63(4), 841-843 (2009
249. Saitoh A, Sarles E, Capparelli E, et al. CYP2B6 genetic variants are associated with nevirapine pharmacokinetics and clinical response in HIV-1-infected children. AIDS 21(16), 2191-2199 (2007
250. Dong BJ, Zheng Y, Hughes MD, et al. Nevirapine pharmacokinetics and risk of rash and hepatitis among HIV-infected sub-Saharan African women. AIDS 26(7), 833-841 (2012
251. Martin AM, Nolan D, James I, et al. Predisposition to nevirapine hypersensitivity associated with HLA-DRB1.0101 and abrogated by low CD4 T-cell counts. AIDS 19(1), 97-99 (2005
252. Littera R, Carcassi C, Masala A, et al. HLA-dependent hypersensitivity to nevirapine in Sardinian HIV patients. AIDS 20(12), 1621-1626 (2006
253. Likanonsakul S, Rattanatham T, Feangvad S, et al. HLA-Cw 04 allele associated with nevirapine-induced rash in HIV-infected Thai patients. AIDS Res. Ther. 6, 22 (2009
254. Pavlos R, Rive C, McKinnon E, et al. Specific binding characteristics of HLA alleles associated with nevirapine hypersensitivity. Presented at: Conference on Retroviruses and Opportunistic Infections, Boston, MA, USA, 3-6 March 2014 (Abstract 804
255. Antela A, Ocampo A, Gómez R, et al. Liver toxicity after switching or simplifying to nevirapine-based therapy is not related to CD4 cell counts: Results of the TOSCANA study. HIV Clin. Trials 11(1), 11-17 (2010
256. Wit FW, Kesselring AM, Gras L, et al. Discontinuation of nevirapine because of hypersensitivity reactions in patients with prior treatment experience, compared with treatment-naive patients: The ATHENA cohort study. Clin. Infect. Dis. 46(6), 933-940 (2008
257. Kesselring AM, Wit FW, Sabin CA, et al. Risk factors for treatment-limiting toxicities in patients starting nevirapine-containing antiretroviral therapy. AIDS 23(13), 1689-1699 (2009
258. Lubomirov R, di Iulio J, Fayet A, et al. ADME pharmacogenetics: Investigation of the pharmacokinetics of the antiretroviral agent lopinavir coformulated with ritonavir. Pharmacogenet. Genomics 20(4), 217-230 (2010
259. Bertrand J, Treluyer J-M, Panhard X, et al. Influence of pharmacogenetics on indinavir disposition and short-Term response in HIV patients initiating HAART. Eur. J. Clin. Pharmacol. 65(7), 667-678 (2009
260. Elens L, Yombi J-C, Lison D, Wallemacq P, Vandercam B, Haufroid V. Association between ABCC2 polymorphism and lopinavir accumulation in peripheral blood mononuclear cells of HIV-infected patients. Pharmacogenomics 10(10), 1589-1597 (2009
261. Hartkoorn RC, San Kwan W, Shallcross V, et al. HIV protease inhibitors are substrates for OATP1A2, OATP1B1 and OATP1B3 and lopinavir plasma concentrations are influenced by SLCO1B1 polymorphisms. Pharmacogenet. Genomics 20(2), 112-120 (2010
262. Kohlrausch FB, De Cássia Estrela R, Barroso PF, Suarez- Kurtz G. The impact of SLCO1B1 polymorphisms on the plasma concentration of lopinavir and ritonavir in HIV-infected men. Br. J. Clin. Pharmacol. 69(1), 95-98 (2010
263. Arnedo M, Taffe P, Sahli R, et al. Contribution of 20 single nucleotide polymorphisms of 13 genes to dyslipidemia associated with antiretroviral therapy. Pharmacogenet. Genomics 17(9), 755-764 (2007
264. Tarr PE, Rotger M, Telenti A. Dyslipidemia in HIV-infected individuals: From pharmacogenetics to pharmacogenomics. Pharmacogenomics 11(4), 587-594 (2010
265. Kile DA, MaWhinney S, Aquilante CL, Rower JE, Castillo-Mancilla JR, Anderson PL. A population pharmacokinetic-pharmacogenetic analysis of atazanavir. AIDS Res. Hum. Retroviruses 28(10), 1227-1234 (2012
266. Annaert P, Ye Z, Stieger B, Augustijns P. Interaction of HIV Protease Inhibitors with OATP1B1, 1B3, and 2B1. Xenobiotica 40(3), 163-176 (2010
267. Burt T, Dhillon S. Pharmacogenomics in early-phase clinical development. Pharmacogenomics 14(9), 1085-1097 (2013
268. Phillips EJ, Mallal SA. Pharmacogenetics of drug hypersensitivity. Pharmacogenomics 11(7), 973-987 (2010